Based on the Jazz Pharmaceuticals PLC stock forecast from 13 analysts, the average analyst target price for Jazz Pharmaceuticals PLC is USD 171.37 over the next 12 months. Jazz Pharmaceuticals PLC’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Jazz Pharmaceuticals PLC is Slightly Bullish , which is based on 8 positive signals and 6 negative signals. At the last closing, Jazz Pharmaceuticals PLC’s stock price was USD 125.82. Jazz Pharmaceuticals PLC’s stock price has changed by +2.42% over the past week, +2.47% over the past month and +3.98% over the last year.
No recent analyst target price found for Jazz Pharmaceuticals PLC
No recent average analyst rating found for Jazz Pharmaceuticals PLC
Company Overview Jazz Pharmaceuticals PLC
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Zepzelca for the treatment of patients with select relapsed/refractory solid tumors based on limited response in three solid tumor cohorts; JZP815, a pan-RAF kinase inhibitor that targets components of the mitogen-activated protein kinase; JZP898, a conditionally-activated interferon alpha molecule; Epidiolex to treat LGS, DS, and TSC; Suvecaltamide to treat parkinson's disease tremor; JZP150, a fatty acid amide hydrolase inhibitor program to treat post-traumatic stress disorder; and JZP441 to treat narcolepsy, IH, and other sleep disorders. The company has licensing and collaboration agreements with XL-protein GmbH to extend the plasma half-life of selected asparaginase product candidates; Redx Pharma plc for preclinical activities Ras/Raf/MAP kinase pathway program; and Autifony Therapeutics Limited on discovering and developing drug candidates targeting two different ion channel targets associated with neurological disorders. The company was incorporated in 2003 and is headquartered in Dublin, Ireland. Read Less
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hyperso...Read More
Frequently Asked Questions About Jazz Pharmaceuticals PLC (JAZZ) Stock
Based on ratings from 13 analysts Jazz Pharmaceuticals PLC's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bullish . The stock has 22 buy, sell and 5 hold ratings.
Unfortunately we do not have enough data on JAZZ's stock to indicate if its a good dividend stock.
Based on targets from 13 analysts, the average taret price for JAZZ is USD 171.37 over the next 12 months. The maximum analyst target price is USD 230 while the minimum anlayst target price is USD 113.
JAZZ stock's Price/Earning ratio is 17.43.
Our analysis grades JAZZ stock's Price / Earning ratio at F. This means that JAZZ stock's Price/Earning ratio is above 69% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this JAZZ may be a overvalued for its sector.
The last closing price of JAZZ's stock was USD 125.82.
The most recent market capitalization for JAZZ is USD 7.44B.
Based on targets from 13 analysts, the average taret price for JAZZ is projected at USD 171.37 over the next 12 months.
This means that JAZZ's stock price may go up by +36.20% over the next 12 months.
We can't find any ETFs which contains Jazz Pharmaceuticals PLC's stock.
As per our most recent records Jazz Pharmaceuticals PLC has 2,800 Employees.
Jazz Pharmaceuticals PLC's registered address is Waterloo Exchange, Dublin, Ireland, D04 E5W7.
You can get more information about it from Jazz Pharmaceuticals PLC's website at https://www.jazzpharma.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior capital utilization
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Jazz Pharmaceuticals PLC (JAZZ) Stock
Based on ratings from 13 analysts Jazz Pharmaceuticals PLC's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bullish . The stock has 22 buy, sell and 5 hold ratings.
Unfortunately we do not have enough data on JAZZ's stock to indicate if its a good dividend stock.
Based on targets from 13 analysts, the average taret price for JAZZ is USD 171.37 over the next 12 months. The maximum analyst target price is USD 230 while the minimum anlayst target price is USD 113.
JAZZ stock's Price/Earning ratio is 17.43.
Our analysis grades JAZZ stock's Price / Earning ratio at F. This means that JAZZ stock's Price/Earning ratio is above 69% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this JAZZ may be a overvalued for its sector.
The last closing price of JAZZ's stock was USD 125.82.
The most recent market capitalization for JAZZ is USD 7.44B.
Based on targets from 13 analysts, the average taret price for JAZZ is projected at USD 171.37 over the next 12 months.
This means that JAZZ's stock price may go up by +36.20% over the next 12 months.
We can't find any ETFs which contains Jazz Pharmaceuticals PLC's stock.
As per our most recent records Jazz Pharmaceuticals PLC has 2,800 Employees.
Jazz Pharmaceuticals PLC's registered address is Waterloo Exchange, Dublin, Ireland, D04 E5W7.
You can get more information about it from Jazz Pharmaceuticals PLC's website at https://www.jazzpharma.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for JAZZ !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
